Paradigm Biopharmaceuticals Limited
PBIGF
$0.2083
$0.00633.12%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 5.40K | 5.60K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 5.40K | 5.60K | -- | -- | -- |
| Cost of Revenue | 6.10K | 6.30K | 3.00K | 3.00K | -- |
| Gross Profit | -700.00 | -700.00 | -3.00K | -3.00K | -- |
| SG&A Expenses | 768.20K | 789.90K | 987.60K | 985.60K | 1.23M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.07M | 2.13M | 4.93M | 4.92M | 16.34M |
| Operating Income | -2.07M | -2.13M | -4.93M | -4.92M | -16.34M |
| Income Before Tax | -1.93M | -1.98M | -3.19M | -3.19M | -16.30M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.93M | -1.98M | -3.19M | -3.19M | -16.30M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.93M | -1.98M | -3.19M | -3.19M | -16.30M |
| EBIT | -2.07M | -2.13M | -4.93M | -4.92M | -16.34M |
| EBITDA | -2.04M | -2.10M | -4.91M | -4.90M | -16.32M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.05 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.03 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.05 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.03 |
| Average Basic Shares Outstanding | 354.05M | 354.05M | 286.78M | 286.78M | 299.79M |
| Average Diluted Shares Outstanding | 354.05M | 354.05M | 286.78M | 286.78M | 299.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |